JP2016531563A - 肝臓癌関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体及びこれを含む癌予防または治療用組成物 - Google Patents
肝臓癌関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体及びこれを含む癌予防または治療用組成物 Download PDFInfo
- Publication number
- JP2016531563A JP2016531563A JP2016525279A JP2016525279A JP2016531563A JP 2016531563 A JP2016531563 A JP 2016531563A JP 2016525279 A JP2016525279 A JP 2016525279A JP 2016525279 A JP2016525279 A JP 2016525279A JP 2016531563 A JP2016531563 A JP 2016531563A
- Authority
- JP
- Japan
- Prior art keywords
- sirna
- cancer
- oligo rna
- rna structure
- bmi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2013-0080579 | 2013-07-09 | ||
| KR20130080579A KR20150006742A (ko) | 2013-07-09 | 2013-07-09 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| PCT/KR2014/006145 WO2015005669A1 (en) | 2013-07-09 | 2014-07-09 | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531563A true JP2016531563A (ja) | 2016-10-13 |
| JP2016531563A5 JP2016531563A5 (enExample) | 2016-12-01 |
Family
ID=52280271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525279A Withdrawn JP2016531563A (ja) | 2013-07-09 | 2014-07-09 | 肝臓癌関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体及びこれを含む癌予防または治療用組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160168573A1 (enExample) |
| EP (1) | EP3019611A4 (enExample) |
| JP (1) | JP2016531563A (enExample) |
| KR (1) | KR20150006742A (enExample) |
| CN (1) | CN105765069A (enExample) |
| SG (1) | SG11201600076WA (enExample) |
| WO (1) | WO2015005669A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116898870A (zh) | 2017-07-28 | 2023-10-20 | 雷莫内克斯生物制药有限公司 | 用于预防或治疗肝癌的药物组合物 |
| CN110964816A (zh) * | 2019-11-20 | 2020-04-07 | 深圳市鲲鹏未来科技有限公司 | 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法 |
| CN111189808B (zh) * | 2019-12-25 | 2022-12-06 | 宁夏医科大学总医院 | 与肝脏损伤、肝细胞凋亡相关特异蛋白分子标志物筛选方法 |
| CN111596059A (zh) * | 2020-05-19 | 2020-08-28 | 上海长海医院 | Gankyrin蛋白作为新型分子标志物在前列腺癌预后评估中的应用 |
| KR102329524B1 (ko) * | 2021-08-06 | 2021-11-23 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 |
| WO2023013818A1 (ko) * | 2021-08-06 | 2023-02-09 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 |
| CA3267582A1 (en) * | 2022-09-28 | 2024-04-18 | Ohio State Innovation Foundation | RNA NANOSTRUCTURES AND COMPLEXES FOR THE TREATMENT OF CANCER METASTASES |
| CN117281792A (zh) * | 2023-07-25 | 2023-12-26 | 浙江大学 | 一种用于增强肝癌免疫疗法治疗效果的纳米制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0692972B2 (en) * | 1993-04-02 | 2012-03-21 | AntiCancer, Inc. | Method for delivering beneficial compositions to hair follicles |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| CA2581190A1 (en) * | 2004-09-29 | 2006-04-13 | Alza Corporation | Microparticles and nanoparticles containing a lipopolymer |
| AU2008206695A1 (en) * | 2007-01-16 | 2008-07-24 | Proteologics Ltd | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
| US8871509B2 (en) * | 2009-11-06 | 2014-10-28 | Chung-Ang University-Academy Corporation Foundation | Nanoparticle-based gene delivery systems |
| CA2859127C (en) * | 2011-12-15 | 2017-04-25 | Bioneer Corporation | Novel oligonucleotide conjugates and use thereof |
-
2013
- 2013-07-09 KR KR20130080579A patent/KR20150006742A/ko not_active Withdrawn
-
2014
- 2014-07-09 EP EP14822311.8A patent/EP3019611A4/en not_active Withdrawn
- 2014-07-09 US US14/902,808 patent/US20160168573A1/en not_active Abandoned
- 2014-07-09 CN CN201480048986.8A patent/CN105765069A/zh active Pending
- 2014-07-09 SG SG11201600076WA patent/SG11201600076WA/en unknown
- 2014-07-09 WO PCT/KR2014/006145 patent/WO2015005669A1/en not_active Ceased
- 2014-07-09 JP JP2016525279A patent/JP2016531563A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20160168573A1 (en) | 2016-06-16 |
| WO2015005669A1 (en) | 2015-01-15 |
| EP3019611A1 (en) | 2016-05-18 |
| EP3019611A4 (en) | 2017-06-14 |
| SG11201600076WA (en) | 2016-02-26 |
| KR20150006742A (ko) | 2015-01-19 |
| CN105765069A (zh) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5952423B2 (ja) | 新規オリゴヌクレオチド接合体およびその用途 | |
| JP6060178B2 (ja) | 高効率のナノ粒子型二本鎖オリゴrna構造体およびその製造方法 | |
| JP6457645B2 (ja) | GST−π遺伝子を調節するためのRNA干渉剤 | |
| JP2016531563A (ja) | 肝臓癌関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体及びこれを含む癌予防または治療用組成物 | |
| JP2020062023A (ja) | 呼吸器疾患関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体およびこれを含む呼吸器疾患予防または治療用組成物 | |
| JP2016523557A (ja) | 肝臓癌関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体及びこれを含む癌予防または治療用組成物 | |
| JP2016028605A (ja) | Rna干渉効果が高い脂質修飾2本鎖rna | |
| JP2016523557A5 (enExample) | ||
| BR112016000160B1 (pt) | estrutura de oligonucleotídeo tipo nanopartícula melhorada tendo alta eficiência e método para a preparação da mesma | |
| KR20130085004A (ko) | 자성나노입자-SAMiRNA 복합체 및 그 제조방법 | |
| JP2023002587A (ja) | アンフィレグリン遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物 | |
| JP2018537104A (ja) | 高活性及びオフターゲット削減のためのsiRNA構造 | |
| JP2013515498A (ja) | c−Metの発現を阻害するsiRNA及びこれを含む抗癌組成物 | |
| CN103314109A (zh) | 用于抑制Hif1α表达的siRNA和含有其的抗癌组合物 | |
| KR20230138462A (ko) | 암 치료를 위한 템플릿 지시된 면역조절 | |
| US20190351067A1 (en) | Multifunctional RNA Nanoparticles and Methods for Treating Cancer and Therapeutic Resistant Cancer | |
| JP2023533124A (ja) | 二本鎖オリゴヌクレオチド及びこれを含むコロナウイルス感染症-19(covid-19)治療用組成物 | |
| JP7554850B2 (ja) | アンフィレギュリン特異的な二本鎖オリゴヌクレオチド構造体を含む肥満関連疾患の予防及び治療用組成物 | |
| JP6600389B2 (ja) | GST−π遺伝子を調節するためのRNA干渉剤 | |
| KR101722948B1 (ko) | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 | |
| KR20160147674A (ko) | STAT3 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체, 이를 포함하는 조성물 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160907 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160907 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160907 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20170626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170626 |